Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...

Top scientists from have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes.

Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid ...

With one in eight adults taking drugs like Ozempic and Mounjaro, emerging evidence shows that the medication has potential to ...

Denmark's GDP grew by the most in four years as Novo Nordisk continues to boost the small Nordic country's economy.

Global Biotech is surging as policy fears fade and innovation takes centre stage. Here’s what’s driving the comeback into ...

Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader at the nexus of serialization ...